Natixis Advisors LLC Purchases 27,789 Shares of Eli Lilly and Company $LLY

Natixis Advisors LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 728,451 shares of the company’s stock after acquiring an additional 27,789 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Natixis Advisors LLC’s holdings, making the stock its 13th largest holding. Natixis Advisors LLC’s holdings in Eli Lilly and Company were worth $782,852,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Pincus Capital Management LP bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $2,746,000. Strategic Advisors LLC increased its position in shares of Eli Lilly and Company by 4.0% during the 4th quarter. Strategic Advisors LLC now owns 1,993 shares of the company’s stock valued at $2,142,000 after purchasing an additional 77 shares during the last quarter. Allen Investment Management LLC increased its position in shares of Eli Lilly and Company by 29.3% during the 4th quarter. Allen Investment Management LLC now owns 8,541 shares of the company’s stock valued at $9,178,000 after purchasing an additional 1,936 shares during the last quarter. AXQ Capital LP bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $1,815,000. Finally, Fielder Capital Group LLC grew its position in Eli Lilly and Company by 6.9% during the 4th quarter. Fielder Capital Group LLC now owns 497 shares of the company’s stock worth $534,000 after acquiring an additional 32 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on LLY shares. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Wells Fargo & Company raised their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Jefferies Financial Group raised their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday, May 21st. Finally, Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company Trading Down 2.3%

NYSE LLY opened at $1,079.96 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,149.10. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a 50 day simple moving average of $959.18 and a two-hundred day simple moving average of $1,010.74. The stock has a market cap of $1.02 trillion, a P/E ratio of 38.36, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the business posted $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark now covers Eli Lilly’s full obesity drug portfolio, including the newly approved oral therapy Foundayo and injectable Zepbound. With all three major U.S. PBMs covering Lilly’s obesity medicines, the company gets broader insurance access and a stronger commercial outlook for its weight-loss franchise. PBM Coverage Of Eli Lilly Obesity Drugs Reshapes Growth And Pricing Outlook
• Positive Sentiment: Lilly announced a major Phase 3 win for Retevmo (selpercatinib), which cut the risk of recurrence or death by 83% in early-stage RET fusion-positive lung cancer. The data could expand the drug’s use and add to Lilly’s oncology growth pipeline. Unit of China’s Haisco, Eli Lilly sign collaboration, licensing deals
• Positive Sentiment: The company also announced new licensing and collaboration deals in Asia, including agreements with Hanmi and Haisco. Investors may view the deal-making as evidence that Lilly is actively building its next wave of products beyond obesity drugs. Lilly Continues Its Acquisition Spree, Inks Two Asia Partnerships Today
• Neutral Sentiment: Several commentary pieces highlighted Lilly as one of the market’s top momentum stocks, and noted bullish analyst sentiment and strong Q1 revenue growth. These reports reinforce positive expectations, but they do not add materially new fundamentals. These 8 Words From Eli Lilly’s CEO Have Wall Street Turning Bullish
• Neutral Sentiment: One industry update noted Novo Nordisk’s oral GLP-1 pill is still outselling Lilly’s competing tablet, though growth is slowing. That suggests the obesity market remains highly competitive even as Lilly expands access. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
• Negative Sentiment: There was also a widely circulated note that Lilly shares had been trading down earlier in the period, but the article did not point to a new company-specific problem. Insider selling data in one report may also weigh on sentiment, though it is not necessarily a near-term fundamental issue. Eli Lilly and Company (NYSE:LLY) Trading Down 1.9% – What’s Next?

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.